IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about EDQM issued CEP Certificate for Sitagliptin Phosphate Monohydrate
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IOL Chemicals and Pharmaceuticals has received a CEP (Certificate of Suitability) from the EDQM (European Directorate for the Quality of Medicines) for Sitagliptin Phosphate Monohydrate, an active pharmaceutical ingredient (API) used in diabetes treatment. The CEP certifies that the company's manufacturing process and product quality meet European Pharmacopoeia standards. This approval enables the company to supply this API to pharmaceutical companies in European markets. Sitagliptin is a high-value API used in blockbuster diabetes drugs such as Januvia.
Positive for the company as it opens up European markets for a high-demand diabetes API, potentially boosting export revenues and strengthening IOL's position as a global API supplier. Could support long-term growth in the company's pharma segment.